NCT03126695 - A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 12, 2017

Primary Completion Date

July 24, 2017

Study Completion Date

July 24, 2017

Conditions

Sickle Cell Disease

Interventions

DRUG

Ticagrelor granule

A P2Y12 receptor inhibitor provided as granule for suspension.

DRUG

Ticagrelor pediatric tablets

A P2Y12 receptor inhibitor provided as pediatric tablets to be swallowed whole.

DRUG

Ticagrelor pediatric tablets suspended in water

A P2Y12 receptor inhibitor provided as pediatric tablets suspended in water.

DRUG

Ticagrelor immediate release (IR) tablets (Commercial tablet)

A P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (unstable angina, non-ST (S and T waves) elevation MI or ST elevation MI) and in patients with a history of MI

Trial Locations (1)

14050

Research Site, Berlin